Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
M&A / Property Routine +

Vector Science and Therapeutics Announces Listing on the TSX Venture Exchange

Vector Science RTO Raises $2.3M Amidst Biotech Device Ambitions

By The Northwire Desk — AI Analysis Apr 24, 2026 · 13:02 PAIN
Executive Summary
  • Vector Science and Therapeutics Corp. completed a qualifying transaction via a three-cornered merger, effectively becoming a public company on the TSX Venture Exchange under ticker "PAIN".
  • The transaction was an arm's length reverse takeover of Vector Science and Therapeutics Inc. by OpenSesame Acquisition Corp. shareholders.
  • Concurrent non-brokered financing raised gross proceeds of C$2,310,500 via 23,105,000 Subscription Receipts at C$0.10 per receipt.
  • Share issuance resulted in approximately 153,259,380 shares outstanding post-transaction.
  • Subscription receipts convert into Resulting Issuer Shares and warrants with an exercise price of C$0.25, exercisable until June 27, 2028.
  • Finders fees included $85,240 in cash and 840,400 warrants issued to finders.
  • Corporate governance changes include a name change effective April 23, 2026, and an auditor transition from Davidson & Company LLP to McGovern Hurley LLP.
  • Trading is expected to resume on the TSXV around April 28, 2026.
Material Impact
  • The completion of the RTO provides necessary public market access for capital raising but does not inherently validate the underlying asset quality or commercial viability.
  • The concurrent financing amount (C$2.3M) is modest for a company claiming development in biomechanical devices and drug delivery, suggesting limited runway without further dilution.
  • Significant share issuance (147,759,380 Resulting Issuer Shares) indicates substantial dilution to existing shell shareholders, which typically suppresses immediate stock price appreciation.
  • The warrant structure creates future overhang; 23,105,000 warrants at C$0.25 exercise price represent potential additional equity issuance if the share price exceeds this level before June 2028.
  • Escrow arrangements (60,350,000 shares) and TSXV regime holdings (2,500,000 shares) indicate locked-up capital that will eventually enter circulation, creating future selling pressure risks.
  • Auditor change from Davidson & Company LLP to McGovern Hurley LLP warrants monitoring; while common in RTOs, it can sometimes signal a need for fresh scrutiny on financial reporting during the transition.
PAIN · Price
Company Overview
  • The company operates under the name Vector Science and Therapeutics Corp., formerly OpenSesame Acquisition Corp.
  • Flagship focus areas include biomechanical device development, drug delivery systems, and commercialization of medical solutions.
  • Management led by CEO Bill Jackson claims expertise in device development and commercial execution.
  • Operating subsidiary is named VST Operating Corp.
  • The company aims to be a defining force in patient care innovation but currently lacks specific product details or clinical stage data in the provided news release.
Read the original news release →

More from

Jun 30, 2026 · 08:55

Vector Science files provisional patent for magnetic transdermal peptide delivery, targeting De Novo FDA pathway amid rapid pipeline expansion.

M&A / Property Jun 22, 2026 · 07:40

From penny-stock SPAC shell to peptide-play: Vector Science bets on sports-medicine branding and cGMP manufacturing to monetize an $80B market.

M&A / Property May 13, 2026 · 10:48

Vector Science Secures Manufacturing Access Amid Related-Party Scrutiny

Other May 11, 2026 · 08:50

Vector swaps $6M capex for a cGMP key, unlocking shelf-stable peptides and signaling a manufacturing-first game plan.

Other May 11, 2026 · 08:50

/C O R R E C T I O N -- Vector Sciences & Therapeutics/

M&A / Property May 01, 2026 · 09:26

Vector Science Files Patent for Pancreatic Cancer Platform Following TSXV Listing

Other